Biotech News
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
– FREEDOM2-DM1 5 mg/kg cohort data expected in Q1 2026 – – Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected in 2H 2026 – – FREEDOM2 trial open in South Korea, Australia, and New Zealand – – Well-funded with $148.5M of cash as of December 31,